BILE DUCT CANCER
Clinical trials for BILE DUCT CANCER explained in plain language.
Never miss a new study
Get alerted when new BILE DUCT CANCER trials appear
Sign up with your email to follow new studies for BILE DUCT CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New immunotherapy cocktail targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment. The goal is to find the safest dose and see if it can shrink tumors in people with advanced cancers like melanoma, lung, and ovarian canc…
Matched conditions: BILE DUCT CANCER
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 26, 2026 06:54 UTC
-
New hope for advanced cancers: immunotherapy drug shows promise in large trial
Disease control OngoingThis study tests the drug pembrolizumab in about 1,600 people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink tumors and to identify biomarkers that predict response. Participants receive pembrolizumab and are m…
Matched conditions: BILE DUCT CANCER
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 06:51 UTC
-
Can a Two-Drug punch wake up 'Cold' tumors?
Disease control TerminatedThis study tests whether combining two drugs—atezolizumab (an immunotherapy) and tivozanib (a targeted therapy)—can shrink tumors in cancers that typically don't respond to immunotherapy alone. About 29 adults with advanced bile duct, gallbladder, breast, neuroendocrine, ovarian,…
Matched conditions: BILE DUCT CANCER
Phase: PHASE1, PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated May 26, 2026 06:43 UTC